Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093795 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
A Phase 3 study, sponsored by NSABP Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,894
- Enrollment target
NCT00093795 is a Phase 3 study that has completed, run by NSABP Foundation. The registered enrollment target is 4,894 participants.
The verdict
NCT00093795, a Phase 3 study, has completed, sponsored by NSABP Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,894 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase III trial is studying three different combination chemotherapy regimens and comparing how well they work in treating women who have undergone surgery for node-positive breast cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Docetaxel
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,894 participants |
| Start Date | 2004-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093795
The ClinicalTrials.gov registry entry for NCT00093795 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,894 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00093795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093795 about?
NCT00093795 is a clinical study titled "Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as docetaxel, doxorubicin , cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This...
What is the current status of trial NCT00093795?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,894 participants. The study started on 2004-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT00093795?
The interventions under investigation include: Cyclophosphamide (DRUG), Docetaxel (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00093795?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.